Bioventus Inc. (BVS) 10-Year Financial Performance & Capital Metrics

BVS • • Industrial / General

HealthcareMedical DevicesOrthopedic & Musculoskeletal DevicesJoint Reconstruction & Orthopedic Implants

AboutBioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.Show more

Revenue $573M +11.9%
EBITDA $38M +254.3%
Net Income -$34M +78.5%
EPS (Diluted) -0.52 +79.1%
Gross Margin 67.72% +5.7%
EBITDA Margin 6.55% +237.9%
Operating Margin -2.09% +86.9%
Net Margin -5.85% +80.8%
ROE -16.49% +66.6%
ROIC -1.7% +80.9%
Debt/Equity 1.81 +1.3%
Interest Coverage -0.31 +84.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 11.0%

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y11%

3Y9.98%

TTM1.58%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM118.85%

EPS CAGR

10Y-

5Y-

3Y-

TTM118.78%

ROCE

10Y Avg-1.07%

5Y Avg-4.03%

3Y Avg-9.16%

Latest-2.08%

Peer Comparison

Joint Reconstruction & Orthopedic Implants

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
SYKStryker Corporation	138.62B	362.49	46.71	10.23%	12.07%	13.51%	2.52%	0.68
SNNSmith & Nephew plc	13.96B	32.89	34.99	4.7%	6.88%	14.44%	4.34%	0.63
ZBHZimmer Biomet Holdings, Inc.	17.59B	88.75	20.03	3.85%	10.05%	6.31%	6.5%	0.50
CNMDCONMED Corporation	1.32B	42.55	9.99	5%	4.75%	6.35%	11.68%	0.94
DHAIDIH Holding US, Inc.	6.7K	0.00	-0.00	-2.5%	-13.8%
LFWDLifeward Ltd.	13.23M	0.72	-0.22	85.24%	-121.82%	-233.98%		0.05
ANIKAnika Therapeutics, Inc.	137.43M	9.53	-2.49	-0.73%	-40.83%	-22.5%		0.17
SNWVSANUWAVE Health, Inc.	237.99M	27.75	-3.95	59.99%	-17.06%		0.83%

Profit & Loss

	Dec 2014	Dec 2015	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	242.89M	253.65M	319.18M	340.14M	321.16M	430.9M	512.12M	512.35M	573.28M
Revenue Growth %	-	0.04%	0.26%	0.07%	-0.06%	0.34%	0.19%	0%	0.12%
Cost of Goods Sold+	74.61M	74.34M	84.17M	90.94M	87.64M	128.19M	181.04M	184.15M	185.05M
COGS % of Revenue	0.31%	0.29%	0.26%	0.27%	0.27%	0.3%	0.35%	0.36%	0.32%
Gross Profit+	168.28M	179.31M	235.01M	249.21M	233.52M	302.71M	331.08M	328.19M	388.23M
Gross Margin %	0.69%	0.71%	0.74%	0.73%	0.73%	0.7%	0.65%	0.64%	0.68%
Gross Profit Growth %	-	0.07%	0.31%	0.06%	-0.06%	0.3%	0.09%	-0.01%	0.18%
Operating Expenses+	165.49M	173.76M	209.5M	218.01M	212.28M	290.64M	498.31M	409.92M	400.2M
OpEx % of Revenue	0.68%	0.69%	0.66%	0.64%	0.66%	0.67%	0.97%	0.8%	0.7%
Selling, General & Admin	147.06M	148.44M	191.67M	198.47M	193.08M	254.25M	332.13M	303.88M	327.09M
SG&A % of Revenue	0.61%	0.59%	0.6%	0.58%	0.6%	0.59%	0.65%	0.59%	0.57%
Research & Development	9.46M	14.75M	8.1M	11.05M	11.2M	19.04M	23.85M	13.45M	13.64M
R&D % of Revenue	0.04%	0.06%	0.03%	0.03%	0.03%	0.04%	0.05%	0.03%	0.02%
Other Operating Expenses	8.97M	10.57M	9.74M	8.48M	8M	17.35M	142.33M	92.59M	59.47M
Operating Income+	20K	-16.59M	25.5M	31.19M	21.24M	12.06M	-167.23M	-81.72M	-11.98M
Operating Margin %	0%	-0.07%	0.08%	0.09%	0.07%	0.03%	-0.33%	-0.16%	-0.02%
Operating Income Growth %	-	-830.4%	2.54%	0.22%	-0.32%	-0.43%	-14.87%	0.51%	0.85%
EBITDA+	28.84M	16.49M	54.74M	61.51M	49.88M	46.94M	-111.84M	-24.36M	37.58M
EBITDA Margin %	0.12%	0.07%	0.17%	0.18%	0.16%	0.11%	-0.22%	-0.05%	0.07%
EBITDA Growth %	-	-0.43%	2.32%	0.12%	-0.19%	-0.06%	-3.38%	0.78%	2.54%
D&A (Non-Cash Add-back)	28.82M	33.08M	29.24M	30.32M	28.64M	34.88M	55.4M	57.37M	49.55M
EBIT	616K	-17.74M	25.28M	31.27M	25.66M	10.6M	-177M	-80.44M	-10.33M
Net Interest Income+	-11.97M	-14.23M	-19.17M	-21.58M	-9.75M	-1.11M	-12.02M	-40.68M	-38.79M
Interest Income	0	0	0	0	0	0	0	0	0
Interest Expense	11.97M	14.23M	19.17M	21.58M	9.75M	1.11M	12.02M	40.68M	38.79M
Other Income/Expense	-11.37M	-15.38M	-19.4M	-21.5M	-5.32M	-2.57M	-21.79M	-39.39M	-37.15M
Pretax Income+	-11.35M	-31.97M	6.11M	9.69M	15.91M	9.49M	-189.03M	-121.11M	-49.13M
Pretax Margin %	-0.05%	-0.13%	0.02%	0.03%	0.05%	0.02%	-0.37%	-0.24%	-0.09%
Income Tax+	1.55M	2.14M	1.66M	1.58M	1.19M	-1.97M	-44.37M	85K	-5.29M
Effective Tax Rate %	1.14%	1.07%	-2%	0.71%	1.03%	2.04%	0.84%	1.29%	0.68%
Net Income+	-12.9M	-34.11M	-12.21M	6.85M	16.41M	19.38M	-158.7M	-156.23M	-33.54M
Net Margin %	-0.05%	-0.13%	-0.04%	0.02%	0.05%	0.04%	-0.31%	-0.3%	-0.06%
Net Income Growth %	-	-1.64%	0.64%	1.56%	1.4%	0.18%	-9.19%	0.02%	0.79%
Net Income (Continuing)	-12.9M	-34.11M	4.44M	8.11M	14.72M	11.45M	-144.65M	-121.2M	-43.83M
Discontinued Operations	0	0	0	0	0	-1.87M	-54.78M	-59.49M	0
Minority Interest	0	0	0	2.63M	1.92M	74.86M	86.98M	47.53M	37.66M
EPS (Diluted)+	-0.30	-0.69	-0.22	0.12	0.44	-0.15	-2.59	-2.49	-0.52
EPS Growth %	-	-1.3%	0.68%	1.55%	2.67%	-1.34%	-16.27%	0.04%	0.79%
EPS (Basic)	-0.30	-0.69	-0.22	0.12	0.44	-0.15	-2.59	-2.49	-0.52
Diluted Shares Outstanding	55.63M	55.63M	56.83M	56.83M	37.7M	45.47M	61.39M	62.65M	65.36M
Basic Shares Outstanding	55.63M	55.63M	56.83M	56.83M	37.7M	45.47M	61.39M	62.65M	65.36M
Dividend Payout Ratio	-	-	-	1.33%	1.21%	0.02%	-	-	-

Balance Sheet

	Dec 2014	Dec 2015	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	95.23M	99.43M	148.35M	183.03M	211.79M	263.1M	272.57M	268M	275.61M
Cash & Short-Term Investments	15.77M	4.95M	42.77M	64.52M	86.84M	43.93M	30.19M	36.96M	41.58M
Cash Only	15.77M	4.95M	42.77M	64.52M	86.84M	43.93M	30.19M	36.96M	41.58M
Short-Term Investments	0	0	0	0	0	0	0	0	0
Accounts Receivable	47.08M	54.51M	73.04M	85.13M	88.28M	124.96M	136.29M	122.79M	127.39M
Days Sales Outstanding	70.74	78.44	83.53	91.35	100.33	105.85	97.14	87.48	81.11
Inventory	26.67M	35.18M	27.4M	27.33M	29.12M	61.69M	84.77M	91.33M	92.47M
Days Inventory Outstanding	130.49	172.71	118.8	109.68	121.28	175.64	170.9	181.03	182.4
Other Current Assets	0	343K	224K	0	0	20.28M	16.89M	16.91M	14.16M
Total Non-Current Assets+	335.19M	387.93M	294.37M	289.37M	282.67M	962.76M	1.1B	542.91M	452.35M
Property, Plant & Equipment	10.43M	9.6M	4.76M	19.76M	21.84M	40.17M	44.15M	49.96M	33.52M
Fixed Asset Turnover	23.29x	26.42x	67.07x	17.22x	14.71x	10.73x	11.60x	10.26x	17.10x
Goodwill	49.95M	58.69M	49.8M	49.8M	49.8M	147.62M	7.46M	7.46M	7.46M
Intangible Assets	274.33M	319.15M	237.03M	216.51M	191.65M	695.19M	639.85M	482.35M	404.73M
Long-Term Investments	0	0	2.78M	3.31M	19.38M	29.29M	2.64M	0	0
Other Non-Current Assets	298K	393K	0	0	0	50M	405.98M	3.14M	1.89M
Total Assets+	430.42M	487.35M	442.72M	472.41M	494.47M	1.23B	1.37B	810.91M	727.96M
Asset Turnover	0.56x	0.52x	0.72x	0.72x	0.65x	0.35x	0.37x	0.63x	0.79x
Asset Growth %	-	0.13%	-0.09%	0.07%	0.05%	1.48%	0.12%	-0.41%	-0.1%
Total Current Liabilities+	52.16M	87.69M	65.43M	89.02M	122.59M	180.86M	304.02M	175.5M	210.4M
Accounts Payable	5.38M	8.37M	8.21M	6.44M	4.42M	16.91M	36.7M	23.04M	23.69M
Days Payables Outstanding	26.33	41.08	35.59	25.85	18.42	48.16	73.99	45.66	46.73
Short-Term Debt	7.19M	36.48M	5.25M	10M	15M	18.04M	33.06M	27.85M	27.34M
Deferred Revenue (Current)	-1000K	0	0	0	0	0	0	0	0
Other Current Liabilities	21.57M	26.77M	25.73M	22.98M	20.86M	46.48M	151.07M	34.23M	51.13M
Current Ratio	1.83x	1.13x	2.27x	2.06x	1.73x	1.45x	0.90x	1.53x	1.31x
Quick Ratio	1.31x	0.73x	1.85x	1.75x	1.49x	1.11x	0.62x	1.01x	0.87x
Cash Conversion Cycle	174.9	210.07	166.74	175.18	203.19	233.33	194.06	222.84	216.78
Total Non-Current Liabilities+	200.78M	207.32M	232.03M	237.78M	227.72M	511.21M	656.41M	414.3M	331.95M
Long-Term Debt	162.3M	157.61M	189.58M	187.97M	173.38M	339.64M	385.01M	367M	308.29M
Capital Lease Obligations	803K	1.22M	0	0	0	0	0	0	0
Deferred Tax Liabilities	9.33M	8.78M	3.96M	3.87M	3.36M	133.52M	2.25M	1.21M	564K
Other Non-Current Liabilities	28.35M	39.72M	38.49M	45.94M	50.98M	38.05M	269.15M	46.08M	23.1M
Total Liabilities	252.93M	295.01M	297.46M	326.79M	350.31M	692.07M	960.43M	589.79M	542.35M
Total Debt+	170.98M	196.51M	194.83M	197.97M	188.38M	357.68M	418.07M	394.85M	335.63M
Net Debt	155.2M	191.56M	152.05M	133.44M	101.54M	313.75M	387.88M	357.88M	294.05M
Debt / Equity	0.96x	1.02x	1.34x	1.36x	1.31x	0.67x	1.01x	1.79x	1.81x
Debt / EBITDA	5.93x	11.92x	3.56x	3.22x	3.78x	7.62x	-	-	8.93x
Net Debt / EBITDA	5.38x	11.62x	2.78x	2.17x	2.04x	6.68x	-	-	7.83x
Interest Coverage	0.00x	-1.17x	1.33x	1.45x	2.18x	10.85x	-13.91x	-2.01x	-0.31x
Total Equity+	177.49M	192.34M	145.27M	145.62M	144.16M	533.79M	412.22M	221.12M	185.6M
Equity Growth %	-	0.08%	-0.24%	0%	-0.01%	2.7%	-0.23%	-0.46%	-0.16%
Book Value per Share	3.19	3.46	2.56	2.56	3.82	11.74	6.71	3.53	2.84
Total Shareholders' Equity	177.49M	192.34M	145.27M	142.98M	142.24M	458.92M	325.24M	173.59M	147.94M
Common Stock	113.4M	113.37M	285.15M	285.15M	285.17M	75K	78K	79K	82K
Retained Earnings	-56.49M	-91.84M	-139.82M	-141.7M	-144.54M	-6.6M	-165.31M	-321.54M	-355.08M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	14K	-650K	-65K	-465K	1.61M	179K	-110K	794K	-2.57M
Minority Interest	0	0	0	2.63M	1.92M	74.86M	86.98M	47.53M	37.66M

Cash Flow

	Dec 2014	Dec 2015	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	15.11M	18.92M	45.19M	40.71M	71.8M	22.99M	-13.54M	15.34M	38.8M
Operating CF Margin %	0.06%	0.07%	0.14%	0.12%	0.22%	0.05%	-0.03%	0.03%	0.07%
Operating CF Growth %	-	0.25%	1.39%	-0.1%	0.76%	-0.68%	-1.59%	2.13%	1.53%
Net Income	-12.9M	-34.11M	4.44M	8.11M	14.72M	11.45M	-144.65M	-121.2M	-318K
Depreciation & Amortization	28.82M	33.08M	29.24M	30.32M	28.64M	34.88M	55.4M	57.37M	49.55M
Stock-Based Compensation	0	0	14.32M	0	10.1M	19.84M	17.59M	2.72M	10.06M
Deferred Taxes	-701K	-432K	-79K	-348K	0	-9.76M	-46.66M	-2.38M	-5.39M
Other Non-Cash Items	11.9M	31.03M	-5.59M	16.2M	3.02M	-18.28M	134.52M	82.01M	-3.33M
Working Capital Changes	-12.01M	-10.65M	2.85M	-13.57M	15.31M	-15.14M	-29.73M	-3.18M	-11.78M
Change in Receivables	-217K	-11.27M	-12.13M	-14.91M	0	-20.05M	-17.67M	10.05M	-10.67M
Change in Inventory	10.65M	-5.73M	3.26M	-1.43M	0	3.18M	-18.62M	0	-16.43M
Change in Payables	3.04M	5.18M	12.15M	6.65M	0	0	0	0	0
Cash from Investing+	-31.38M	-60.19M	-6.1M	-7.91M	-20.5M	-283.76M	-116.44M	15.81M	22.96M
Capital Expenditures	-1.16M	-2.12M	-6.06M	-2.34M	-16.58M	-13.52M	-1.48M	-7.36M	-1.01M
CapEx % of Revenue	0%	0.01%	0.02%	0.01%	0.05%	0.03%	0%	0.01%	0%
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	-19.67M	-6.61M	-40K	-6.43M	-3.92M	-7.37M	-114.96M	-11.51M	23.97M
Cash from Financing+	-6.64M	31.25M	-13.26M	-10.95M	-29.57M	273.37M	62.08M	-26.65M	-54.58M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	-2.4M	-1.02M	-7.85M	-9.14M	-19.89M	-367K	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	-1.73M	32.94M	-160K	-448K	317K	-1.88M	-3.37M	-4.17M	2.56M
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-5.72M	11.48M	39.13M	32.37M	51.13M	2.1M	-15.02M	7.98M	37.79M
FCF Margin %	-0.02%	0.05%	0.12%	0.1%	0.16%	0%	-0.03%	0.02%	0.07%
FCF Growth %	-	3.01%	2.41%	-0.17%	0.58%	-0.96%	-8.15%	1.53%	3.73%
FCF per Share	-0.10	0.21	0.69	0.57	1.36	0.05	-0.24	0.13	0.58
FCF Conversion (FCF/Net Income)	-1.17x	-0.55x	-3.70x	5.94x	4.38x	1.19x	0.09x	-0.10x	-1.16x
Interest Paid	31.9M	15.63M	17.27M	15.45M	7.49M	0	0	0	0
Taxes Paid	785K	2.61M	1.94M	1.58M	1.54M	0	0	0	0

Key Ratios

Metric	2014	2015	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-7.27%	-18.45%	-7.23%	4.71%	11.33%	5.72%	-33.55%	-49.34%	-16.49%
Return on Invested Capital (ROIC)	0%	-3.47%	5.62%	8.12%	6.07%	1.65%	-15.22%	-8.89%	-1.7%
Gross Margin	69.28%	70.69%	73.63%	73.27%	72.71%	70.25%	64.65%	64.06%	67.72%
Net Margin	-5.31%	-13.45%	-3.82%	2.01%	5.11%	4.5%	-30.99%	-30.49%	-5.85%
Debt / Equity	0.96x	1.02x	1.34x	1.36x	1.31x	0.67x	1.01x	1.79x	1.81x
Interest Coverage	0.00x	-1.17x	1.33x	1.45x	2.18x	10.85x	-13.91x	-2.01x	-0.31x
FCF Conversion	-1.17x	-0.55x	-3.70x	5.94x	4.38x	1.19x	0.09x	-0.10x	-1.16x
Revenue Growth	-	4.43%	25.83%	6.57%	-5.58%	34.17%	18.85%	0.04%	11.89%

Revenue by Segment

	2021	2022	2023	2024
U.S.	-	-	-	506.81M
U.S. Growth	-	-	-	-
International	-	-	-	66.47M
International Growth	-	-	-	-
Pain Treatments	221.61M	-	-	-
Pain Treatments Growth	-	-	-	-
Restorative Therapies	121.57M	-	-	-
Restorative Therapies Growth	-	-	-	-
Surgical Solutions	87.72M	-	-	-
Surgical Solutions Growth	-	-	-	-

Revenue by Geography

	2021	2022	2023	2024
UNITED STATES	387.55M	126.21M	449.86M	506.81M
UNITED STATES Growth	-	-67.43%	256.45%	12.66%
Non-US	43.34M	14.95M	62.48M	66.47M
Non-US Growth	-	-65.51%	317.93%	6.38%

Frequently Asked Questions

Growth & Financials

Bioventus Inc. (BVS) reported $563.8M in revenue for fiscal year 2024. This represents a 132% increase from $242.9M in 2014.

Bioventus Inc. (BVS) grew revenue by 11.9% over the past year. This is steady growth.

Yes, Bioventus Inc. (BVS) is profitable, generating $7.8M in net income for fiscal year 2024 (-5.9% net margin).

Dividend & Returns

Bioventus Inc. (BVS) has a return on equity (ROE) of -16.5%. Negative ROE indicates the company is unprofitable.

Bioventus Inc. (BVS) generated $53.5M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Bioventus Inc. (BVS) 10-Year Financial Performance & Capital Metrics

BVS • • Industrial / General

HealthcareMedical DevicesOrthopedic & Musculoskeletal DevicesJoint Reconstruction & Orthopedic Implants

Revenue $573M +11.9%
EBITDA $38M +254.3%
Net Income -$34M +78.5%
EPS (Diluted) -0.52 +79.1%
Gross Margin 67.72% +5.7%
EBITDA Margin 6.55% +237.9%
Operating Margin -2.09% +86.9%
Net Margin -5.85% +80.8%
ROE -16.49% +66.6%
ROIC -1.7% +80.9%
Debt/Equity 1.81 +1.3%
Interest Coverage -0.31 +84.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 11.0%

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y11%

3Y9.98%

TTM1.58%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM118.85%

EPS CAGR

10Y-

5Y-

3Y-

TTM118.78%

ROCE

10Y Avg-1.07%

5Y Avg-4.03%

3Y Avg-9.16%

Latest-2.08%

Peer Comparison

Joint Reconstruction & Orthopedic Implants

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
SYKStryker Corporation	138.62B	362.49	46.71	10.23%	12.07%	13.51%	2.52%	0.68
SNNSmith & Nephew plc	13.96B	32.89	34.99	4.7%	6.88%	14.44%	4.34%	0.63
ZBHZimmer Biomet Holdings, Inc.	17.59B	88.75	20.03	3.85%	10.05%	6.31%	6.5%	0.50
CNMDCONMED Corporation	1.32B	42.55	9.99	5%	4.75%	6.35%	11.68%	0.94
DHAIDIH Holding US, Inc.	6.7K	0.00	-0.00	-2.5%	-13.8%
LFWDLifeward Ltd.	13.23M	0.72	-0.22	85.24%	-121.82%	-233.98%		0.05
ANIKAnika Therapeutics, Inc.	137.43M	9.53	-2.49	-0.73%	-40.83%	-22.5%		0.17
SNWVSANUWAVE Health, Inc.	237.99M	27.75	-3.95	59.99%	-17.06%		0.83%

Profit & Loss

	Dec 2014	Dec 2015	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	242.89M	253.65M	319.18M	340.14M	321.16M	430.9M	512.12M	512.35M	573.28M
Revenue Growth %	-	0.04%	0.26%	0.07%	-0.06%	0.34%	0.19%	0%	0.12%
Cost of Goods Sold+	74.61M	74.34M	84.17M	90.94M	87.64M	128.19M	181.04M	184.15M	185.05M
COGS % of Revenue	0.31%	0.29%	0.26%	0.27%	0.27%	0.3%	0.35%	0.36%	0.32%
Gross Profit+	168.28M	179.31M	235.01M	249.21M	233.52M	302.71M	331.08M	328.19M	388.23M
Gross Margin %	0.69%	0.71%	0.74%	0.73%	0.73%	0.7%	0.65%	0.64%	0.68%
Gross Profit Growth %	-	0.07%	0.31%	0.06%	-0.06%	0.3%	0.09%	-0.01%	0.18%
Operating Expenses+	165.49M	173.76M	209.5M	218.01M	212.28M	290.64M	498.31M	409.92M	400.2M
OpEx % of Revenue	0.68%	0.69%	0.66%	0.64%	0.66%	0.67%	0.97%	0.8%	0.7%
Selling, General & Admin	147.06M	148.44M	191.67M	198.47M	193.08M	254.25M	332.13M	303.88M	327.09M
SG&A % of Revenue	0.61%	0.59%	0.6%	0.58%	0.6%	0.59%	0.65%	0.59%	0.57%
Research & Development	9.46M	14.75M	8.1M	11.05M	11.2M	19.04M	23.85M	13.45M	13.64M
R&D % of Revenue	0.04%	0.06%	0.03%	0.03%	0.03%	0.04%	0.05%	0.03%	0.02%
Other Operating Expenses	8.97M	10.57M	9.74M	8.48M	8M	17.35M	142.33M	92.59M	59.47M
Operating Income+	20K	-16.59M	25.5M	31.19M	21.24M	12.06M	-167.23M	-81.72M	-11.98M
Operating Margin %	0%	-0.07%	0.08%	0.09%	0.07%	0.03%	-0.33%	-0.16%	-0.02%
Operating Income Growth %	-	-830.4%	2.54%	0.22%	-0.32%	-0.43%	-14.87%	0.51%	0.85%
EBITDA+	28.84M	16.49M	54.74M	61.51M	49.88M	46.94M	-111.84M	-24.36M	37.58M
EBITDA Margin %	0.12%	0.07%	0.17%	0.18%	0.16%	0.11%	-0.22%	-0.05%	0.07%
EBITDA Growth %	-	-0.43%	2.32%	0.12%	-0.19%	-0.06%	-3.38%	0.78%	2.54%
D&A (Non-Cash Add-back)	28.82M	33.08M	29.24M	30.32M	28.64M	34.88M	55.4M	57.37M	49.55M
EBIT	616K	-17.74M	25.28M	31.27M	25.66M	10.6M	-177M	-80.44M	-10.33M
Net Interest Income+	-11.97M	-14.23M	-19.17M	-21.58M	-9.75M	-1.11M	-12.02M	-40.68M	-38.79M
Interest Income	0	0	0	0	0	0	0	0	0
Interest Expense	11.97M	14.23M	19.17M	21.58M	9.75M	1.11M	12.02M	40.68M	38.79M
Other Income/Expense	-11.37M	-15.38M	-19.4M	-21.5M	-5.32M	-2.57M	-21.79M	-39.39M	-37.15M
Pretax Income+	-11.35M	-31.97M	6.11M	9.69M	15.91M	9.49M	-189.03M	-121.11M	-49.13M
Pretax Margin %	-0.05%	-0.13%	0.02%	0.03%	0.05%	0.02%	-0.37%	-0.24%	-0.09%
Income Tax+	1.55M	2.14M	1.66M	1.58M	1.19M	-1.97M	-44.37M	85K	-5.29M
Effective Tax Rate %	1.14%	1.07%	-2%	0.71%	1.03%	2.04%	0.84%	1.29%	0.68%
Net Income+	-12.9M	-34.11M	-12.21M	6.85M	16.41M	19.38M	-158.7M	-156.23M	-33.54M
Net Margin %	-0.05%	-0.13%	-0.04%	0.02%	0.05%	0.04%	-0.31%	-0.3%	-0.06%
Net Income Growth %	-	-1.64%	0.64%	1.56%	1.4%	0.18%	-9.19%	0.02%	0.79%
Net Income (Continuing)	-12.9M	-34.11M	4.44M	8.11M	14.72M	11.45M	-144.65M	-121.2M	-43.83M
Discontinued Operations	0	0	0	0	0	-1.87M	-54.78M	-59.49M	0
Minority Interest	0	0	0	2.63M	1.92M	74.86M	86.98M	47.53M	37.66M
EPS (Diluted)+	-0.30	-0.69	-0.22	0.12	0.44	-0.15	-2.59	-2.49	-0.52
EPS Growth %	-	-1.3%	0.68%	1.55%	2.67%	-1.34%	-16.27%	0.04%	0.79%
EPS (Basic)	-0.30	-0.69	-0.22	0.12	0.44	-0.15	-2.59	-2.49	-0.52
Diluted Shares Outstanding	55.63M	55.63M	56.83M	56.83M	37.7M	45.47M	61.39M	62.65M	65.36M
Basic Shares Outstanding	55.63M	55.63M	56.83M	56.83M	37.7M	45.47M	61.39M	62.65M	65.36M
Dividend Payout Ratio	-	-	-	1.33%	1.21%	0.02%	-	-	-

Balance Sheet

	Dec 2014	Dec 2015	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	95.23M	99.43M	148.35M	183.03M	211.79M	263.1M	272.57M	268M	275.61M
Cash & Short-Term Investments	15.77M	4.95M	42.77M	64.52M	86.84M	43.93M	30.19M	36.96M	41.58M
Cash Only	15.77M	4.95M	42.77M	64.52M	86.84M	43.93M	30.19M	36.96M	41.58M
Short-Term Investments	0	0	0	0	0	0	0	0	0
Accounts Receivable	47.08M	54.51M	73.04M	85.13M	88.28M	124.96M	136.29M	122.79M	127.39M
Days Sales Outstanding	70.74	78.44	83.53	91.35	100.33	105.85	97.14	87.48	81.11
Inventory	26.67M	35.18M	27.4M	27.33M	29.12M	61.69M	84.77M	91.33M	92.47M
Days Inventory Outstanding	130.49	172.71	118.8	109.68	121.28	175.64	170.9	181.03	182.4
Other Current Assets	0	343K	224K	0	0	20.28M	16.89M	16.91M	14.16M
Total Non-Current Assets+	335.19M	387.93M	294.37M	289.37M	282.67M	962.76M	1.1B	542.91M	452.35M
Property, Plant & Equipment	10.43M	9.6M	4.76M	19.76M	21.84M	40.17M	44.15M	49.96M	33.52M
Fixed Asset Turnover	23.29x	26.42x	67.07x	17.22x	14.71x	10.73x	11.60x	10.26x	17.10x
Goodwill	49.95M	58.69M	49.8M	49.8M	49.8M	147.62M	7.46M	7.46M	7.46M
Intangible Assets	274.33M	319.15M	237.03M	216.51M	191.65M	695.19M	639.85M	482.35M	404.73M
Long-Term Investments	0	0	2.78M	3.31M	19.38M	29.29M	2.64M	0	0
Other Non-Current Assets	298K	393K	0	0	0	50M	405.98M	3.14M	1.89M
Total Assets+	430.42M	487.35M	442.72M	472.41M	494.47M	1.23B	1.37B	810.91M	727.96M
Asset Turnover	0.56x	0.52x	0.72x	0.72x	0.65x	0.35x	0.37x	0.63x	0.79x
Asset Growth %	-	0.13%	-0.09%	0.07%	0.05%	1.48%	0.12%	-0.41%	-0.1%
Total Current Liabilities+	52.16M	87.69M	65.43M	89.02M	122.59M	180.86M	304.02M	175.5M	210.4M
Accounts Payable	5.38M	8.37M	8.21M	6.44M	4.42M	16.91M	36.7M	23.04M	23.69M
Days Payables Outstanding	26.33	41.08	35.59	25.85	18.42	48.16	73.99	45.66	46.73
Short-Term Debt	7.19M	36.48M	5.25M	10M	15M	18.04M	33.06M	27.85M	27.34M
Deferred Revenue (Current)	-1000K	0	0	0	0	0	0	0	0
Other Current Liabilities	21.57M	26.77M	25.73M	22.98M	20.86M	46.48M	151.07M	34.23M	51.13M
Current Ratio	1.83x	1.13x	2.27x	2.06x	1.73x	1.45x	0.90x	1.53x	1.31x
Quick Ratio	1.31x	0.73x	1.85x	1.75x	1.49x	1.11x	0.62x	1.01x	0.87x
Cash Conversion Cycle	174.9	210.07	166.74	175.18	203.19	233.33	194.06	222.84	216.78
Total Non-Current Liabilities+	200.78M	207.32M	232.03M	237.78M	227.72M	511.21M	656.41M	414.3M	331.95M
Long-Term Debt	162.3M	157.61M	189.58M	187.97M	173.38M	339.64M	385.01M	367M	308.29M
Capital Lease Obligations	803K	1.22M	0	0	0	0	0	0	0
Deferred Tax Liabilities	9.33M	8.78M	3.96M	3.87M	3.36M	133.52M	2.25M	1.21M	564K
Other Non-Current Liabilities	28.35M	39.72M	38.49M	45.94M	50.98M	38.05M	269.15M	46.08M	23.1M
Total Liabilities	252.93M	295.01M	297.46M	326.79M	350.31M	692.07M	960.43M	589.79M	542.35M
Total Debt+	170.98M	196.51M	194.83M	197.97M	188.38M	357.68M	418.07M	394.85M	335.63M
Net Debt	155.2M	191.56M	152.05M	133.44M	101.54M	313.75M	387.88M	357.88M	294.05M
Debt / Equity	0.96x	1.02x	1.34x	1.36x	1.31x	0.67x	1.01x	1.79x	1.81x
Debt / EBITDA	5.93x	11.92x	3.56x	3.22x	3.78x	7.62x	-	-	8.93x
Net Debt / EBITDA	5.38x	11.62x	2.78x	2.17x	2.04x	6.68x	-	-	7.83x
Interest Coverage	0.00x	-1.17x	1.33x	1.45x	2.18x	10.85x	-13.91x	-2.01x	-0.31x
Total Equity+	177.49M	192.34M	145.27M	145.62M	144.16M	533.79M	412.22M	221.12M	185.6M
Equity Growth %	-	0.08%	-0.24%	0%	-0.01%	2.7%	-0.23%	-0.46%	-0.16%
Book Value per Share	3.19	3.46	2.56	2.56	3.82	11.74	6.71	3.53	2.84
Total Shareholders' Equity	177.49M	192.34M	145.27M	142.98M	142.24M	458.92M	325.24M	173.59M	147.94M
Common Stock	113.4M	113.37M	285.15M	285.15M	285.17M	75K	78K	79K	82K
Retained Earnings	-56.49M	-91.84M	-139.82M	-141.7M	-144.54M	-6.6M	-165.31M	-321.54M	-355.08M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	14K	-650K	-65K	-465K	1.61M	179K	-110K	794K	-2.57M
Minority Interest	0	0	0	2.63M	1.92M	74.86M	86.98M	47.53M	37.66M

Cash Flow

	Dec 2014	Dec 2015	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	15.11M	18.92M	45.19M	40.71M	71.8M	22.99M	-13.54M	15.34M	38.8M
Operating CF Margin %	0.06%	0.07%	0.14%	0.12%	0.22%	0.05%	-0.03%	0.03%	0.07%
Operating CF Growth %	-	0.25%	1.39%	-0.1%	0.76%	-0.68%	-1.59%	2.13%	1.53%
Net Income	-12.9M	-34.11M	4.44M	8.11M	14.72M	11.45M	-144.65M	-121.2M	-318K
Depreciation & Amortization	28.82M	33.08M	29.24M	30.32M	28.64M	34.88M	55.4M	57.37M	49.55M
Stock-Based Compensation	0	0	14.32M	0	10.1M	19.84M	17.59M	2.72M	10.06M
Deferred Taxes	-701K	-432K	-79K	-348K	0	-9.76M	-46.66M	-2.38M	-5.39M
Other Non-Cash Items	11.9M	31.03M	-5.59M	16.2M	3.02M	-18.28M	134.52M	82.01M	-3.33M
Working Capital Changes	-12.01M	-10.65M	2.85M	-13.57M	15.31M	-15.14M	-29.73M	-3.18M	-11.78M
Change in Receivables	-217K	-11.27M	-12.13M	-14.91M	0	-20.05M	-17.67M	10.05M	-10.67M
Change in Inventory	10.65M	-5.73M	3.26M	-1.43M	0	3.18M	-18.62M	0	-16.43M
Change in Payables	3.04M	5.18M	12.15M	6.65M	0	0	0	0	0
Cash from Investing+	-31.38M	-60.19M	-6.1M	-7.91M	-20.5M	-283.76M	-116.44M	15.81M	22.96M
Capital Expenditures	-1.16M	-2.12M	-6.06M	-2.34M	-16.58M	-13.52M	-1.48M	-7.36M	-1.01M
CapEx % of Revenue	0%	0.01%	0.02%	0.01%	0.05%	0.03%	0%	0.01%	0%
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	-19.67M	-6.61M	-40K	-6.43M	-3.92M	-7.37M	-114.96M	-11.51M	23.97M
Cash from Financing+	-6.64M	31.25M	-13.26M	-10.95M	-29.57M	273.37M	62.08M	-26.65M	-54.58M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	-2.4M	-1.02M	-7.85M	-9.14M	-19.89M	-367K	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	-1.73M	32.94M	-160K	-448K	317K	-1.88M	-3.37M	-4.17M	2.56M
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-5.72M	11.48M	39.13M	32.37M	51.13M	2.1M	-15.02M	7.98M	37.79M
FCF Margin %	-0.02%	0.05%	0.12%	0.1%	0.16%	0%	-0.03%	0.02%	0.07%
FCF Growth %	-	3.01%	2.41%	-0.17%	0.58%	-0.96%	-8.15%	1.53%	3.73%
FCF per Share	-0.10	0.21	0.69	0.57	1.36	0.05	-0.24	0.13	0.58
FCF Conversion (FCF/Net Income)	-1.17x	-0.55x	-3.70x	5.94x	4.38x	1.19x	0.09x	-0.10x	-1.16x
Interest Paid	31.9M	15.63M	17.27M	15.45M	7.49M	0	0	0	0
Taxes Paid	785K	2.61M	1.94M	1.58M	1.54M	0	0	0	0

Key Ratios

Metric	2014	2015	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-7.27%	-18.45%	-7.23%	4.71%	11.33%	5.72%	-33.55%	-49.34%	-16.49%
Return on Invested Capital (ROIC)	0%	-3.47%	5.62%	8.12%	6.07%	1.65%	-15.22%	-8.89%	-1.7%
Gross Margin	69.28%	70.69%	73.63%	73.27%	72.71%	70.25%	64.65%	64.06%	67.72%
Net Margin	-5.31%	-13.45%	-3.82%	2.01%	5.11%	4.5%	-30.99%	-30.49%	-5.85%
Debt / Equity	0.96x	1.02x	1.34x	1.36x	1.31x	0.67x	1.01x	1.79x	1.81x
Interest Coverage	0.00x	-1.17x	1.33x	1.45x	2.18x	10.85x	-13.91x	-2.01x	-0.31x
FCF Conversion	-1.17x	-0.55x	-3.70x	5.94x	4.38x	1.19x	0.09x	-0.10x	-1.16x
Revenue Growth	-	4.43%	25.83%	6.57%	-5.58%	34.17%	18.85%	0.04%	11.89%

Revenue by Segment

	2021	2022	2023	2024
U.S.	-	-	-	506.81M
U.S. Growth	-	-	-	-
International	-	-	-	66.47M
International Growth	-	-	-	-
Pain Treatments	221.61M	-	-	-
Pain Treatments Growth	-	-	-	-
Restorative Therapies	121.57M	-	-	-
Restorative Therapies Growth	-	-	-	-
Surgical Solutions	87.72M	-	-	-
Surgical Solutions Growth	-	-	-	-

Revenue by Geography

	2021	2022	2023	2024
UNITED STATES	387.55M	126.21M	449.86M	506.81M
UNITED STATES Growth	-	-67.43%	256.45%	12.66%
Non-US	43.34M	14.95M	62.48M	66.47M
Non-US Growth	-	-65.51%	317.93%	6.38%

Frequently Asked Questions

Growth & Financials

Bioventus Inc. (BVS) reported $563.8M in revenue for fiscal year 2024. This represents a 132% increase from $242.9M in 2014.

Bioventus Inc. (BVS) grew revenue by 11.9% over the past year. This is steady growth.

Yes, Bioventus Inc. (BVS) is profitable, generating $7.8M in net income for fiscal year 2024 (-5.9% net margin).

Dividend & Returns

Bioventus Inc. (BVS) has a return on equity (ROE) of -16.5%. Negative ROE indicates the company is unprofitable.

Bioventus Inc. (BVS) generated $53.5M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.